lrrk2-protein

📖 Wiki Page

protein1647 wordssynced 2026-04-02

LRRK2 (Dardarin) Protein

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4ea;">LRRK2 — Leucine-Rich Repeat Kinase 2</th></tr>
<tr><td><b>Gene</b></td><td>LRRK2</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q5S007](https://www.uniprot.org/uniprot/Q5S007)</td></tr>
<tr><td><b>PDB Structures</b></td><td>6VP6, 7LHW, 7LI4, 4D0G</td></tr>
<tr><td><b>Molecular Weight</b></td><td>286 kDa (2527 aa)</td></tr>
<tr><td><b>Subcellular Localization</b></td><td>Cytoplasm, membranes, mitochondria</td></tr>
<tr><td><b>Protein Family</b></td><td>ROCO family (Kinase + GTPase)</td></tr>
<tr><td><b>Domain Architecture</b></td><td>ARM, ANK, LRR, ROC, COR, Kinase</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1183 edges</a></td>
</tr>
</table>
</div>

Overview

LRRK2 (Leucine-Rich Repeat Kinase 2), also known as Dardarin (from the Basque "dardara" meaning "trembling"), is a large multi-domain protein encoded by the LRRK2 gene. It belongs to the ROCO protein family and is one of the most significant genetic risk factors for Parkinson's disease[@muller2023].

Domain Architecture

...

LRRK2 (Dardarin) Protein

Overview

Domain Architecture

LRRK2 has a complex multi-domain structure:

Mermaid diagram (expand to render)

Key Domains

| Domain | Function | Disease Relevance |
|--------|----------|-------------------|
| LRR | Protein-protein interactions | Mutations may affect binding |
| ROC | GTPase activity | G2019S increases kinase activity |
| COR | Kinase regulation | Autophosphorylation |
| Kinase | Phosphotransferase | Major drug target |
| WD40 | Scaffold function | C-terminal interactions |

Normal Function

GTPase Activity

ROC domain hydrolyzes GTP to GDP
Regulates protein conformation
Autophosphorylation on multiple residues

Kinase Activity

Phosphorylates substrate proteins
Regulated by GTP binding to ROC domain
Multiple autophosphorylation sites

Cellular Functions

Neuronal Development

Dendritic arborization
Synaptic formation
Axon guidance

Cellular Signaling

MAPK pathway modulation
Wnt signaling
Inflammatory responses

Protein Homeostasis

Macroautophagy regulation
Lysosomal function
Protein sorting

Mitochondrial Function

Mitochondrial dynamics
Mitophagy regulation
Energy metabolism

LRRK2 in Parkinson's Disease

Mermaid diagram (expand to render)

```

Pathogenic Mechanisms

LRRK2 mutations cause PD through multiple mechanisms:

Kinase Hyperactivity

G2019S (most common) increases kinase activity 2-3 fold
Leads to enhanced substrate phosphorylation
Causes toxic gain-of-function

GTPase Dysregulation

Impaired GTP hydrolysis
Constitutive activation
Altered protein interactions

Cellular Dysfunction

Impaired autophagy-lysosome pathway
Mitochondrial dysfunction
Synaptic defects

Neuroinflammation

Microglial activation
Increased cytokine production
Enhanced neuroinflammation

Cellular Consequences

Autophagy Dysregulation

LRRK2 hyperactivation impairs autophagy:

mTORC1 hyperactivation: Prevents autophagy initiation
Lysosomal dysfunction: Reduced clearance
Protein aggregates: Accumulation

Mitochondrial Dysfunction

LRRK2 affects mitochondria:

PINK1/Parkin pathway: Altered mitophagy
Mitochondrial dynamics: fission/fusion imbalance
Energy production: Reduced ATP

Synaptic Failure

Synaptic dysfunction in LRRK2 models:

Vesicle cycling: Impaired release
Spine morphology: Reduced spines
Neurotransmission: Altered signaling

See also: LRRK2 Pathway in Parkinson's Disease.

Common Pathogenic Mutations

| Mutation | Location | Effect | Frequency |
|----------|----------|--------|-----------|
| G2019S | Kinase | Increased activity | 5% familial, 1% sporadic |
| R1441C/G/H | ROC | Impaired GTPase | ~3% familial |
| N1437H | ROC | Reduced activity | Rare |
| G2385R | WD40 | Risk factor | 10% Asian populations |
| R1628P | WD40 | Risk factor | Higher in Asian |

Clinical Features of LRRK2-PD

Motor Symptoms

LRRK2-associated PD shows typical motor features:

Resting tremor
Bradykinesia
Rigidity
Postural instability

Typically slower progression than sporadic PD.

Non-Motor Symptoms

Sleep disorders: REM sleep behavior disorder
Olfactory dysfunction: Anosmia
Autonomic dysfunction: Constipation

Therapeutic Targeting

LRRK2 is a major drug target for PD:

Kinase Inhibitors

Several LRRK2 inhibitors in development:

DNL151/DNL312 (Denali) — Phase 1/2
BIIB122 (Biogen) — Phase 2
MLi-2 — Preclinical tool compound

See also: [LRRK2 Inhibitors](/therapeutics/lrrk2-inhibitors).

Challenges

Brain Penetration: Achieving sufficient CNS exposure

Peripheral Effects: Safety concerns with chronic inhibition

Wild-type Inhibition: Side effects from inhibiting normal LRRK2

Structural Biology

Cryo-EM Structures

Recent advances have revealed the full-length LRRK2 structure[@alessi2023]:

Full-length architecture:

L-shaped dimeric structure
Coordinated Rock-Kinase module
C-terminal WD40 scaffold

Active conformations:

Back-to-back dimer formation
ROC domain dimerization
Kinase activation loop flexibility

GTPase Cycle

The ROC domain functions as a GTPase:

GTP binding:

Promotes LRRK2 dimerization
Activates kinase domain
Enables autophosphorylation

GTP hydrolysis:

ROC domain hydrolyzes GTP to GDP
Regulated by COR domain
Mutations affect hydrolysis rate

GDP release:

Slow release rate
Rate-limiting step
Drug targeting opportunity

Expression Pattern

| Tissue | Expression Level |
|--------|-----------------|
| Brain (highest in substantia nigra) | High |
| Kidney | High |
| Lung | Moderate |
| Heart | Low-Moderate |
| Liver | Low |

Interacting Proteins

LRRK2 interacts with numerous proteins:

α-Synuclein — Pathological interaction
Parkin — Mitophagy regulation
PINK1 — Mitochondrial quality control
14-3-3 proteins — Cytosolic anchoring
VPS35 — Retromer component
Rab proteins — Primary substrates
MAPK components — Signaling pathways
mTOR — Autophagy regulation

LRRK2-Rab Interaction Network

flowchart LR
classDef blue fill:#0a1929,stroke:#01579b,stroke-width:2px
classDef orange fill:#3e2200,stroke:#e65100,stroke-width:2px
classDef green fill:#0e2e10,stroke:#1b5e20,stroke-width:2px
classDef red fill:#3b1114,stroke:#b71c1c,stroke-width:2px

F -.->|"defect"| J["PD Pathogenesis"]:::red
G -.-> J
H -.-> J
I -.-> J

click A "/genes/lrrk2" "LRRK2 Gene"
click A "/proteins/lrrk2-protein" "LRRK2 Protein"
click H "/mechanisms/autophagy-lysosomal-pathway-parkinsons" "Autophagy Pathway"
click J "/diseases/parkinsons-disease" "Parkinson's Disease"

Neuroinflammation in LRRK2-PD

Microglial Activation

LRRK2 is highly expressed in microglia:

Activation markers:

Iba1 upregulation
CD68 expression

Cytokine production:

IL-1β, IL-6, TNF-α

The LRRK2 hyperactivation → microglial activation → chronic inflammation → neuronal loss cascade.

Research Directions

Developing brain-penetrant kinase inhibitors
Understanding kinase substrate specificity
LRRK2 biomarkers development
Gene therapy approaches

LRRK2 in Neurobiology

Neuronal Functions

LRRK2 plays important roles in neurons[@greggio2021]:

Synaptic function:

Presynaptic vesicle cycling
Dendritic spine morphology
neurotransmitter release

Axonal function:

Axon guidance during development
Mitochondrial transport
Cytoskeletal dynamics

Neuronal survival:

MAPK pathway modulation
Autophagy regulation
Stress response

Glial Functions

LRRK2 is highly expressed in glia:

Microglia:

Inflammatory responses
Cytokine production
Phagocytic activity

Astrocytes:

Metabolic support
Potassium buffering
Neurotrophic support

Genetic Modifiers

Modifying Genes

The International LRRK2 Consortium has identified genetic modifiers[@gclass2020]:

Risk modifiers:

GBA variants increase penetrance
SNCA rs356219 increases risk
BST1 variants modify risk

Protective modifiers:

Certain VPS35 variants
Mitochondrial function genes

Penetrance

LRRK2 penetrance is modified by:

Age: ~70% by age 80

Sex: Variable by sex

Genetic background: Modifier genes

Environmental factors: Not yet clear

Brain Atlas Resources

[Allen Human Brain Atlas - LRRK2 Expression](https://human.brain-map.org/microarray/search/show?search_term=LRRK2)
[Allen Cell Type Atlas - LRRK2](https://celltypes.brain-map.org/)
[BrainSpan - LRRK2 Developmental Expression](https://brainspan.org/)
[Allen Mouse Brain Atlas - LRRK2](https://mouse.brain-map.org/)

Clinical Trials and Therapeutic Development

LRRK2-targeted therapies are in various stages of development [@muller2023]:

LRRK2 kinase inhibitors: Several compounds in clinical trials including DNL151 (Denali) and BIIB122 (Biogen) [@sveinbjornsson2022]
Antisense oligonucleotides: ASO therapies targeting LRRK2 mRNA [@zhao2021]
Gene therapy approaches: AAV-mediated delivery of mutant LRRK2 siRNA [@brodacki2020]

Biomarkers

LRRK2 mutation carriers show specific biomarkers [@fang2022]:

CSF biomarkers: Elevated tau protein levels
Neuroimaging: Reduced dopamine transporter binding
Clinical progression: Typically slower progression than sporadic PD

Animal Models

Key LRRK2 models include [@greggio2021]:

Transgenic mice: G2019S mutant mice show dopaminergic neuron loss
Knock-in models: BAC-LRRK2 G2019S mice
Non-human primates: Primate models for translational studies

Pathogenic Variants

The G2019S mutation is the most common pathogenic variant [@kluss2022]:

Prevalence: ~5% of familial PD, ~1% of sporadic PD
Penetrance: Age-dependent, ~70% by age 80
Phenotype: Similar to idiopathic PD but often earlier onset

Future Directions

Research priorities for LRRK2 [@alessi2023]:

Kinase domain structure: Cryo-EM studies of full-length LRRK2
Biological substrates: Identifying all LRRK2 phosphorylation targets
Brain penetration: Developing CNS-penetrant inhibitors

References

["LRRK2 in Parkinson's disease: function and mechanisms (2017)"](https://doi.org/10.1016/j.jparkd.2017.01.001)

["LRRK2 structure and function (2020"](https://doi.org/10.1016/j.neuron.2020.01.019)

["LRRK2 kinase inhibitors in clinical development (2021"](https://doi.org/10.1038/s41582-021-00549-x)

["LRRK2 kinase activity and Parkinson's disease pathogenesis (2019"](https://doi.org/10.1038/s41582-019-0251-7)

["Rab proteins as LRRK2 substrates in Parkinson's disease (2020"](https://doi.org/10.1083/jcb.202004085)

LRRK2 Substrates

Understanding LRRK2 phosphorylation targets is crucial for drug development:

Direct Substrates

Rab proteins (Rab3A, Rab8A, Rab10, Rab12, Rab35)

Key regulators of membrane trafficking
Phosphorylation at conserved Thr/Ser residues
Impaired by pathogenic LRRK2 mutations

MAPK signaling components

ERK, JNK pathway interactions
Neuronal survival signaling

Autophagy proteins

mTORC1 pathway modulation
Lysosomal function regulation

Pathological Substrate Phosphorylation

Hyperphosphorylation of Rab proteins in PD
Disrupted vesicle trafficking
Impaired synaptic function

Biomarkers

LRRK2 biomarker development focuses on:

Fluid Biomarkers

CSF LRRK2 protein levels
Phospho-Rab10 in blood/CSF
Genetic modifiers in CSF

Imaging Biomarkers

PET ligands for LRRK2 (in development)
Neuroinflammation markers

lrrk2-protein

LRRK2 (Dardarin) Protein

Overview

Domain Architecture

LRRK2 (Dardarin) Protein

Overview

Domain Architecture

Key Domains

Normal Function

GTPase Activity

Kinase Activity

Cellular Functions

LRRK2 in Parkinson's Disease

Pathogenic Mechanisms

Cellular Consequences

Autophagy Dysregulation

Mitochondrial Dysfunction

Synaptic Failure

Common Pathogenic Mutations

Clinical Features of LRRK2-PD

Motor Symptoms

Non-Motor Symptoms

Therapeutic Targeting

Kinase Inhibitors

Challenges

Structural Biology

Cryo-EM Structures

GTPase Cycle

Expression Pattern

Interacting Proteins

LRRK2-Rab Interaction Network

Neuroinflammation in LRRK2-PD

Microglial Activation

Research Directions

LRRK2 in Neurobiology

Neuronal Functions

Glial Functions

Genetic Modifiers

Modifying Genes

Penetrance

Brain Atlas Resources

Clinical Trials and Therapeutic Development

Biomarkers

Animal Models

Pathogenic Variants

Future Directions

References

LRRK2 Substrates

Direct Substrates

Pathological Substrate Phosphorylation

Biomarkers

Fluid Biomarkers

Imaging Biomarkers

See Also